# PDUFA dates December 2024: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2024-12

> 91 FDA catalysts are dated in December 2024, including 4 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in December 2024?

PDUFA dates in December 2024: ZYNQUISTA® (zynquista, LXRX) on December 20, 2024; Revuforj® (revumenib, SNDX) on December 26, 2024; CTEXLI® (chenodiol, MIRM) on December 28, 2024; UNLOXCYT (cosibelimab, FBIO) on December 28, 2024. [Calendar and source filings](https://sec-api.dev/fda-calendar/2024-12)

Source: Press release filed with the SEC (EX-99), accession 0001062822-24-000057, https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/pressreleaseearningsq311-1.htm (retrieved 2026-11-12). Last confirmed 2026-02-02. Cite: https://sec-api.dev/fda-calendar/2024-12#answer

## PDUFA dates in December 2024

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| December 20, 2024 | LEXICON PHARMACEUTICALS, INC. | LXRX | ZYNQUISTA® (zynquista) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/pressreleaseearningsq311-1.htm) |
| December 26, 2024 | Syndax Pharmaceuticals Inc | SNDX | Revuforj® (revumenib) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/sndx-ex99_1.htm) |
| December 28, 2024 | Mirum Pharmaceuticals, Inc. | MIRM | CTEXLI® (chenodiol) | CTX, known | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/mirm-20241112xexx991.htm) |
| December 28, 2024 | Fortress Biotech, Inc. | FBIO | UNLOXCYT (cosibelimab) | metastatic or locally advanced cutaneous squamous cell carcinoma | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm) |

## All catalysts in December 2024

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2, 2024 | [SENTI-202 interim data readout](https://sec-api.dev/pdufa/senti-202) | SNTI | relapsed/refractory hematologic malignancies | completed, positive | "SOUTH SAN FRANCISCO, Calif., December 2, 2024 - Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") investigational cell therapy, for the treatment of relapsed/refractory ("R/R") hematologic malignancies including acute myeloid leukemia ("AML")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000114036124048114/ef20039399_ex99-1.htm)) |
| December 2, 2024 | [RASONQUE (daraxonrasib) trial start](https://sec-api.dev/pdufa/daraxonrasib) | RVMD | previously treated, locally advanced or metastatic NSCLC | completed | "Supported by these data, and having finalized the study design disclosed on December 2, 2024, the company has initiated a global, randomized Phase 3 trial (RASolve 301) of daraxonrasib versus docetaxel in patients with previously treated, locally advanced or metastatic NSCLC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000095017025027707/rvmd-ex99_1.htm)) |
| December 3, 2024 | [Chikungunya FDA approval](https://sec-api.dev/pdufa/chikungunya) | VALN |  | completed, approved | "4 Valneva Announces U.S. FDA Approval of World's" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000117184324006682/exh_991.htm)) |
| December 4, 2024 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-49 (Efficacy): submission_status AP, submission_status_date 20241204, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| December 5, 2024 | [NextCure, Inc. NDA/BLA submission](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "On December 5, 2024, NextCure, Inc. (the "Company") updated its corporate presentation to reflect that it has filed an Investigational New Drug Application for its product candidate LNCB74." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1661059/000155837024016026/nxtc-20241205x8k.htm)) |
| December 5, 2024 | [MNPR-101 trial start](https://sec-api.dev/pdufa/mnpr-101) | MNPR |  | completed | "On December 5, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that a first patient was dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/mnpr20241205_8k.htm)) |
| December 9, 2024 | [Acetadote® (acetylcysteine) FDA approval](https://sec-api.dev/pdufa/acetylcysteine) | CPIX |  | completed, approved | ""We are thrilled to announce the FDA approval of this simplified dosing regimen for Acetadote," said A.J. Kazimi, Cumberland's Chief Executive Officer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1087294/000162828024050499/acetadote2bagstudy12924.htm)) |
| December 9, 2024 | [Zelicapavir topline data readout](https://sec-api.dev/pdufa/zelicapavir) | ENTA |  | completed, positive | "As noted in Item 7.01 above, Enanta announced positive topline data from its Phase 2 pediatric study of zelicapavir for the treatment of RSV on December 9, 2024." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1177648/000119312524272936/d706648d8k.htm)) |
| December 9, 2024 | [Acetadote® (acetylcysteine) label expansion decision](https://sec-api.dev/pdufa/acetylcysteine) | CPIX |  | completed, approved | "(December 9, 2024) - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1087294/000162828024050499/acetadote2bagstudy12924.htm)) |
| December 9, 2024 | [Divesiran trial start](https://sec-api.dev/pdufa/divesiran) | SLN |  | completed | "Silence also announces first subject dosed in Phase 2 study of divesiran in PV patients" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312524272929/d911238dex991.htm)) |
| December 9, 2024 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA213051 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20241209, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213051%22)) |
| December 10, 2024 | [Onvansertib interim data readout](https://sec-api.dev/pdufa/onvansertib) | CRDF | first-line RAS-mutated metastatic colorectal cancer | completed, positive | "SAN DIEGO, December 10, 2024 -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213037/000095017024134749/crdf-ex99_2.htm)) |
| December 10, 2024 | [Obicetrapib topline data readout](https://sec-api.dev/pdufa/obicetrapib) | NAMS | established atherosclerotic cardiovascular disease | completed, positive | "On December 10, 2024, we announced positive topline data from our Phase 3 BROADWAY clinical trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1936258/000095017025027339/nams-20241231.htm)) |
| December 11, 2024 | [Aglatimagene besadenovec topline data readout](https://sec-api.dev/pdufa/aglatimagene-besadenovec) | CADL |  | completed, positive | "On December 11, 2024, the Company announced positive topline data from its phase 3 clinical trial in the United States conducted under a SPA with the FDA evaluating patients with newly diagnosed, localized prostate cancer who have an intermediate-to-high risk for progression." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1841387/000119312524274870/d901922d8k.htm)) |
| December 11, 2024 | [Rafael Holdings, Inc. earnings report](https://sec-api.dev/companies/rfl/catalysts) | RFL |  | completed | "NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the first quarter of fiscal year 2025 ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1713863/000121390024107632/ea022434101ex99-1_rafael.htm)) |
| December 11, 2024 | [CHAMPIONS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/csbr/catalysts) | CSBR |  | completed | "Hackensack, NJ - December 11, 2024 - Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/771856/000162828024050789/csbr8-k10312024ex991xq225.htm)) |
| December 11, 2024 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, positive | "On December 11, 2024, we announced positive top line results for the multinational Phase III clinical trial for children 4 to 11 years of age, which has been evaluating leniolisib tablets in 21 children with APDS." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000012/a2024q4pressrelease.htm)) |
| December 11, 2024 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-162 (Efficacy): submission_status AP, submission_status_date 20241211, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| December 12, 2024 | [Alzamend Neuro, Inc. earnings report](https://sec-api.dev/companies/alzn/catalysts) | ALZN |  | completed | "Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), reported its financial results for the second quarter ended October 31, 2024, which were disclosed on a quarterly report on Form 10-Q filed on December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677077/000121465924020439/ex99_1.htm)) |
| December 12, 2024 | [Bridion (sugammadex sodium) label expansion decision](https://sec-api.dev/pdufa/sugammadex) | MRK |  | completed, approved | "NDA022225 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20241212, review_priority PRIORITY; sponsor_name MSD SUB MERCK; product BRIDION (SUGAMMADEX SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022225%22)) |
| December 12, 2024 | [Vtama (tapinarof) label expansion decision](https://sec-api.dev/pdufa/tapinarof) | OGN |  | completed, approved | "NDA215272 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20241212, review_priority STANDARD; sponsor_name ORGANON LLC; product VTAMA (TAPINAROF)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215272%22)) |
| December 13, 2024 | [UNLOXCYT (cosibelimab) FDA approval](https://sec-api.dev/pdufa/cosibelimab) | FBIO | metastatic or locally advanced cutaneous squamous cell carcinoma | completed, approved | "On December 13, 2024, Checkpoint Therapeutics ("Checkpoint"), a majority-controlled subsidiary of Fortress Biotech, Inc. (the "Company" or "Fortress"), announced that the U.S. Food and Drug Administration (the "FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC") who are not candidates for curative surgery or curative radiation." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1429260/000155837024016294/fbio-20241213x8k.htm)) |
| December 13, 2024 | [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) complete response letter (CRL)](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj) | JNJ |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761433_20241213.pdf%22)) |
| December 13, 2024 | [Edesa Biotech, Inc. earnings report](https://sec-api.dev/companies/edsa/catalysts) | EDSA |  | completed | "TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540159/000117184324006945/exh_991.htm)) |
| December 13, 2024 | [CRENESSITY® (crinecerfont) FDA approval](https://sec-api.dev/pdufa/crinecerfont) | NBIX | To treat classic congenital adrenal hyperplasia Press Release | completed, approved | "Crenessity \| crinecerfont \| 12/13/2024 \| To treat classic congenital adrenal hyperplasia Press ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| December 13, 2024 | [Orkambi (ivacaftor; lumacaftor) label expansion decision](https://sec-api.dev/pdufa/ivacaftor-lumacaftor) | VRTX |  | completed, approved | "NDA206038 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20241213, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product ORKAMBI (IVACAFTOR; LUMACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206038%22)) |
| December 16, 2024 | [Tanruprubart topline data readout](https://sec-api.dev/pdufa/tanruprubart) | ANNX |  | completed, positive | "BRISBANE, Calif., December 16, 2024 - Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced positive topline results from a real-world evidence (RWE) study supporting ANX005 as a potential treatment for Guillain-Barré Syndrome (GBS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000119312524279038/d909577dex991.htm)) |
| December 16, 2024 | [Lumvoa™ (veligrotug) topline data readout](https://sec-api.dev/pdufa/veligrotug) | VRDN | chronic TED | completed, positive | "WALTHAM, Mass., December 16, 2024  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/d648282dex991.htm)) |
| December 16, 2024 | [SN301A trial start](https://sec-api.dev/pdufa/sn301a) | SNTI |  | completed | "On December 16, 2024, Senti Biosciences, Inc. (the "Company") issued a press release announcing the first patient dosed in a clinical trial of SN301A in hepatocellular carcinoma in collaboration with Celest Therapeutics (Shanghai) Co. Ltd. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1854270/000185427024000128/snti-20241216.htm)) |
| December 16, 2024 | [Sevasemten topline data readout](https://sec-api.dev/pdufa/sevasemten) | EWTX | Becker muscular dystrophy | completed, positive | "On December 16, 2024, the Company announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710072/000110465924129001/tm2431151d1_8k.htm)) |
| December 16, 2024 | [Brilaroxazine interim data readout](https://sec-api.dev/pdufa/brilaroxazine) | RVPH | schizophrenia | completed, positive | "On December 16, 2024, we announced positive preliminary topline data from, and on June 2, 2025, we announced a positive full dataset and successful completion of, our Phase 3 RECOVER open label extension (the "OLE" or the "OLE Trial") a 1-year study evaluating the long-term safety, tolerability and efficacy of brilaroxazine in patients with schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774925034827/rvph20250930_10q.htm)) |
| December 16, 2024 | [Nomlabofusp interim data readout](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | completed, positive | "Bala Cynwyd, PA, December 16, 2024 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with FA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017024136384/lrmr-ex99_1.htm)) |
| December 17, 2024 | [Levosimendan NDA/BLA acceptance](https://sec-api.dev/pdufa/levosimendan) | TNXP |  | completed | "On December 17, 2024, the Company announced that the FDA accepted the filing of its NDA for TNX-102 SL." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1430306/000199937124015450/tnxp-8k_121724.htm)) |
| December 17, 2024 | [Icovamenib topline data readout](https://sec-api.dev/pdufa/icovamenib) | BMEA | type 2 diabetes | completed, positive | "On December 17, 2024, the Company reported positive topline results from its ongoing Phase II COVALENT-111 Study in patients with type 2 diabetes ("T2D")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1840439/000119312524283008/d827448d8k.htm)) |
| December 18, 2024 | [QYLEKI (QRX003) interim data readout](https://sec-api.dev/pdufa/qrx003) | QNRX |  | completed, positive | "On Dec. 18, 2024, Quoin announced positive interim data from two of its ongoing Netherton Syndrome clinical studies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465925023447/tm259112d1_ex99-1.htm)) |
| December 18, 2024 | [Remestemcel FDA approval](https://sec-api.dev/pdufa/remestemcel) | MESO | children 2 months and older with SR-aGVHD | completed, approved | "Melbourne, Australia; December 19 and New York, USA; December 18, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Administration (FDA) approved Ryoncil® (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000087/exhibit991.htm)) |
| December 18, 2024 | [Vanoglipel topline data readout](https://sec-api.dev/pdufa/vanoglipel) | MTVA | presumed MASH o Top-line data readout | completed, positive | "CAMBRIDGE, Mass., December 18, 2024 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837024016344/mtva-20241218xex99d1.htm)) |
| December 18, 2024 | [Ryoncil (ryoncil) FDA approval](https://sec-api.dev/pdufa/ryoncil) | MESO | SR-aGvHD in children 2 months and older | completed, approved | "Ryoncil® was approved by the FDA on December 18, 2024 as the first MSC therapy in the United States." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm)) |
| December 18, 2024 | [Invokana (canagliflozin) label expansion decision](https://sec-api.dev/pdufa/canagliflozin) | JNJ |  | completed, approved | "NDA204042 SUPPL-43 (Efficacy): submission_status AP, submission_status_date 20241218, review_priority PRIORITY; sponsor_name JANSSEN PHARMS; product INVOKANA (CANAGLIFLOZIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204042%22)) |
| December 18, 2024 | [Invokamet Xr (canagliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/canagliflozin-metformin) | JNJ |  | completed, approved | "NDA205879 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20241218, review_priority PRIORITY; sponsor_name JANSSEN PHARMS; product INVOKAMET XR (CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205879%22)) |
| December 19, 2024 | [Vascular FDA approval](https://sec-api.dev/pdufa/vascular) | HUMA |  | completed, approved | "We received our first FDA approval of the ATEV on December 19, 2024, a full approval for Symvess (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm)) |
| December 19, 2024 | [ADI-270 trial start](https://sec-api.dev/pdufa/adi-270) | ACET | metastatic/advanced ccRCC | completed | "On December 19, 2024 the Company announced the first patient dosed in the Phase 1 clinical trial evaluating ADI-270 in metastatic/ advanced clear cell renal cell carcinoma (ccRCC)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1720580/000095017024138419/acet-20241219.htm)) |
| December 19, 2024 | [TRYNGOLZA (olezarsen) FDA approval](https://sec-api.dev/pdufa/olezarsen) | IONS | familial chylomicronemia syndrome | completed, approved | "On December 19, 2024, Ionis Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved Tryngolza™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/874015/000114036124050057/ef20040455_8k.htm)) |
| December 19, 2024 | [EnGene Therapeutics Inc. earnings report](https://sec-api.dev/companies/engn/catalysts) | ENGN |  | completed | "EX-99.1 enGene Reports Full Year 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1980845/000095017024138446/engn-ex99_1.htm)) |
| December 19, 2024 | [Apazunersen trial start](https://sec-api.dev/pdufa/apazunersen) | RARE |  | completed | "On December 19, 2024, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Company's pivotal Phase 3 Aspire study (NCT06617429) evaluating the efficacy and safety of GTX-102, its investigational antisense oligonucleotide ("ASO") for Angelman syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000095017024138467/rare-20241219.htm)) |
| December 19, 2024 | [Symvess (symvess) FDA approval](https://sec-api.dev/pdufa/symvess) | HUMA | Extremity Vascular Trauma | completed, approved | "Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000181838224000227/huma-20241219xexx991.htm)) |
| December 20, 2024 | [Vanzacaftor FDA approval](https://sec-api.dev/pdufa/vanzacaftor) | VRTX | people with CF 6 years of age and older | completed, approved | "On December 20, 2024, the U.S. Food and Drug Administration approved ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to ALYFTREK." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/vrtx-20241220.htm)) |
| December 20, 2024 | [Izicopan trial start](https://sec-api.dev/pdufa/izicopan) | IFRX |  | completed | "InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708688/000114036124050007/ef20040227_ex99-1.htm)) |
| December 20, 2024 | [ZYNQUISTA® (zynquista) PDUFA date](https://sec-api.dev/pdufa/zynquista) | LXRX |  | scheduled | "Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/pressreleaseearningsq311-1.htm)) |
| December 20, 2024 | [Alhemo (concizumab-mtci) FDA approval](https://sec-api.dev/pdufa/concizumab-mtci) | NVO | For routine prophylaxis to prevent bleeding episodes in hemophilia A and B | completed, approved | "Alhemo \| concizumab-mtci \| 12/20/2024 \| For routine prophylaxis to prevent bleeding episodes in hemophilia A and BDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| December 20, 2024 | [VERTEX PHARMACEUTICALS INC / MA label expansion decision](https://sec-api.dev/companies/vrtx/catalysts) | VRTX | 94 additional non-F508del CFTR mutations | completed, approved | "•On December 20, 2024, Vertex received FDA approval for the expanded use of TRIKAFTA in patients with 94 additional non-F508del CFTR mutations." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/ex-991_q42024.htm)) |
| December 20, 2024 | [Xigduo Xr (dapagliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/dapagliflozin-metformin) | AZN |  | completed, approved | "NDA205649 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product XIGDUO XR (DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205649%22)) |
| December 20, 2024 | [Alyftrek (deutivacaftor; tezacaftor; vanzacaftor calcium) FDA approval](https://sec-api.dev/pdufa/deutivacaftor-tezacaftor-vanzacaftor) | VRTX | For the treatment of cystic fibrosis (CF) in patients 6 years of age and older | completed, approved | "Alyftrek \| vanzacaftor, tezacaftor, and deutivacaftor \| 12/20/2024 \| For the treatment of cystic fibrosis (CF) in patients 6 years of age and olderDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| December 20, 2024 | [Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor) label expansion decision](https://sec-api.dev/pdufa/elexacaftor-ivacaftor-tezacaftor-ivacaftor) | VRTX |  | completed, approved | "NDA217660 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217660%22)) |
| December 20, 2024 | [SKYCLARYS® (omaveloxolone) label expansion decision](https://sec-api.dev/pdufa/omaveloxolone) | BIIB |  | completed, approved | "NDA216718 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority STANDARD; sponsor_name BIOGEN US; product SKYCLARYS (OMAVELOXOLONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216718%22)) |
| December 20, 2024 | [IMCIVREE® (setmelanotide) label expansion decision](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed, approved | "On December 20, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for IMCIVREE to include children as young as 2 years old with syndromic or monogenic obesity due to BBS or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/rytm-20250226xex99d1.htm)) |
| December 20, 2024 | [INPEFA® (sotagliflozin) complete response letter (CRL)](https://sec-api.dev/pdufa/sotagliflozin) | LXRX | type 1 diabetes and CKD | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA210934_20241220.pdf%22)) |
| December 20, 2024 | [Zepbound (tirzepatide) label expansion decision](https://sec-api.dev/pdufa/tirzepatide) | LLY |  | completed, approved | "NDA217806 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22)) |
| December 23, 2024 | [Arixtra (fondaparinux sodium) label expansion decision](https://sec-api.dev/pdufa/fondaparinux) | VTRS |  | completed, approved | "NDA021345 SUPPL-52 (Efficacy): submission_status AP, submission_status_date 20241223, review_priority STANDARD; sponsor_name MYLAN IRELAND LTD; product ARIXTRA (FONDAPARINUX SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021345%22)) |
| December 26, 2024 | [Revuforj® (revumenib) PDUFA date](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, approved | "Positive data from the KMT2Ar AML and ALL patients in the trial supported a New Drug Application (NDA) filing for revumenib in R/R KMT2Ar acute leukemia, which is currently under review by the U.S. FDA with a PDUFA action date of December 26, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/sndx-ex99_1.htm)) |
| December 26, 2024 | [Tevimbra (tislelizumab-jsgr) FDA approval](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761417 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20241226, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761417%22)) |
| December 26, 2024 | [Wezlana (ustekinumab-auub) label expansion decision](https://sec-api.dev/pdufa/ustekinumab-auub) | AMGN |  | completed, approved | "BLA761285 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20241226, review_priority STANDARD; sponsor_name AMGEN INC; product WEZLANA (USTEKINUMAB-AUUB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761285%22)) |
| December 27, 2024 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390024113158/ea022616101ex99-1_citius.htm)) |
| December 27, 2024 | [Girentuximab NDA/BLA submission](https://sec-api.dev/pdufa/girentuximab) | TLX |  | completed | "Kidney cancer imaging, TLX250-CDx (Zircaix®4, 89Zr-girentuximab): Telix submitted a Biologics License Application (BLA) for its renal cancer imaging candidate on 27 December 2024 and continues to target a U.S. commercial launch in H2 20255." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000007/q4bizupdate.htm)) |
| December 27, 2024 | [TEVIMBRA® (tislelizumab) FDA approval](https://sec-api.dev/pdufa/tislelizumab) | ONC |  | completed, approved | "On December 27, 2024, we announced that the U.S. Food and Drug Administration ("FDA") approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (≥1)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000031/bgne-20241231.htm)) |
| December 27, 2024 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390024113159/ea022616501ex99-1_citius.htm)) |
| December 27, 2024 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465924131957/tm2431904d1_ex99-1.htm)) |
| December 27, 2024 | [Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) FDA approval](https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab) | BMY |  | completed, approved | "BLA761381 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20241227, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22)) |
| December 28, 2024 | [CTEXLI® (chenodiol) PDUFA date](https://sec-api.dev/pdufa/chenodiol) | MIRM | CTX, known | scheduled | "•PDUFA date for chenodiol in CTX is December 28, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/mirm-20241112xexx991.htm)) |
| December 28, 2024 | [UNLOXCYT (cosibelimab) PDUFA date](https://sec-api.dev/pdufa/cosibelimab) | FBIO | metastatic or locally advanced cutaneous squamous cell carcinoma | completed, approved | "We could achieve up to two more U.S. FDA approvals in the next nine months, and our next anticipated PDUFA goal date is December 28, 2024, for cosibelimab, an anti-PD-L1 antibody, for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm)) |
| December 30, 2024 | [Onasemnogene abeparvovec topline data readout](https://sec-api.dev/pdufa/onasemnogene-abeparvovec) | NVS |  | completed, positive | "Basel, December 30, 2024 - Novartis today announced positive topline results from the" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1114448/000117184324007096/f6k_123024.htm)) |
| December 30, 2024 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | severe endocrinologic, oncologic, metabolic and neurologic disorders | completed | "REDWOOD CITY, Calif., (December 30, 2024)  Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312524286917/d834253dex991.htm)) |
| December 30, 2024 | [AVMAPKI (avutometinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/avutometinib) | VSTM |  | completed | "On December 30, 2024, the FDA accepted for review our NDA under the accelerated approval pathway and granted priority review for avutometinib and defactinib for treatment of adult patients with recurrent KRAS mt LGSOC who received at least one prior systemic therapy and designated June 30, 2025 as the Prescription Drug User Fee Act ("PDUFA") action date." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231x10k.htm)) |
| December 30, 2024 | [Lifyorli™ (relacorilant) NDA/BLA submission](https://sec-api.dev/pdufa/relacorilant) | CORT | endogenous hypercortisolism | completed | "On December 30, 2024, we submitted to the United States Food and Drug Administration ("FDA") a New Drug Application ("NDA") for a proprietary cortisol modulator we have developed, relacorilant, that, like Korlym, modulates the effects of cortisol by binding at the GR, but has no affinity for the PR and so does not cause PR-related side effects." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1088856/000162828025008167/cort-20241231.htm)) |
| December 31, 2024 | [Pacira BioSciences, Inc. FDA approval](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed, approved | "(7) During the year ended December 31, 2024, the U.S. Food and Drug Administration approved a generic competitor to EXPAREL and a U.S. District Court ruled that one of our patents was not valid." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/pcrx-12312025x991.htm)) |
| December 31, 2024 | [Ersodetug trial start](https://sec-api.dev/pdufa/ersodetug) | RZLT |  | completed | "For the three months ended December 31, 2024, there were de minimis clinical costs incurred for tumor HI related program spend as the Phase 3 upLIFT study had yet to be initiated and clinical costs for the Phase 3 sunRIZE study were lower as we did not complete enrollment of patients until May 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1509261/000110465926014334/rzlt-20251231x10q.htm)) |
| December 31, 2024 | [Tonix Pharmaceuticals Holding Corp. NDA/BLA acceptance](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Subsequent to December 31, 2024, 10,884, 5,758 (as the Company received FDA acceptance of our NDA filing), and 1 warrants with an exercise price of $1,056.00, $1,776.00 and $364,800.00, respectively, expired." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1430306/000199937125002786/tnxp-10k_123124.htm)) |
| December 31, 2024 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of December 31, 2024, two of these milestones had been achieved, as we had filed an investigational new drug application, or IND, in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1645460/000095017025047677/cue-20241231.htm)) |
| December 31, 2024 | [PALVELLA THERAPEUTICS, INC. interim data readout](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | scheduled | "Interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of results that may be expected for the year ending December 31, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1583648/000143774924034891/pirs20240930_10q.htm)) |
| December 31, 2024 | [Kebilidi (eladocagene exuparvovec) FDA approval](https://sec-api.dev/pdufa/eladocagene-exuparvovec) | PTCT |  | completed, approved | "For the year ended December 31, 2024, in connection with our FDA approval of Kebilidi, we received a Priority Review Voucher, or PRV, and sold the PRV for aggregate net proceeds of $148.0 million." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm)) |
| December 31, 2024 | [PMN310 trial start](https://sec-api.dev/pdufa/pmn310) | PMN |  | completed | "This increase is primarily attributable to a $3.5 million increase in spending on our lead program, PMN310, as we completed our Phase 1a clinical trial of PMN310 and initiated the Phase 1b clinical trial of PMN310 during the year ended December 31, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1374339/000155837025004068/pmn-20241231x10k.htm)) |
| December 31, 2024 | [NewAmsterdam Pharma Co N.V. topline data readout](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed, positive | "During the year ended December 31, 2024 the Company announced positive topline results from its Phase 3 BROOKLYN and BROADWAY clinical trials." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1936258/000095017025027339/nams-20241231.htm)) |
| December 31, 2024 | [TECELRA (afamitresgene autoleucel) FDA approval](https://sec-api.dev/pdufa/afamitresgene-autoleucel) | ADAPY |  | completed, approved | "As of December 31, 2024, the Company's only commercially approved product was TECELRA® ("TECELRA"), which was approved by the FDA on August 1, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/adap-20241231x10k.htm)) |
| December 31, 2024 | [Protocol FDA approval](https://sec-api.dev/pdufa/protocol) | AIM |  | completed, approved | "For the years ended December 31, 2024 and 2023, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/946644/000164117225000847/form10-k.htm)) |
| December 31, 2024 | [NXP800 trial start](https://sec-api.dev/pdufa/nxp800) | NVCT |  | completed | "Our main activities through December 31, 2024 have been organizational and capital raising activities and the completion of the in-license agreements for our two drug candidates, NXP800 and NXP900, regulatory filings with the MHRA and FDA, preparation and execution for the Phase 1a and Phase 1b clinical trial for NXP800, which commenced in December 2021 and May 2023, respectively, and Phase 1a clinical trial for NXP900, which commenced in September 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1875558/000155837025001496/tmb-20241231x10k.htm)) |
| December 31, 2024 | [AUCATZYL (obecabtagene autoleucel) FDA approval](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed, approved | "We did not generate any product revenue for the year ended 31 December 2024, as AUCATZYL was approved by the FDA for commercial use on 8 November 2024 and was not launched in the U.S. market until 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/ex991autoluannualreporta.htm)) |
| December 31, 2024 | [TH103 trial start](https://sec-api.dev/pdufa/th103) | KLRS |  | completed | "CRO expenses increased by $2.9 million during the year ended December 31, 2024 as Kalaris initiated its Phase 1 clinical trial in June 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex994.htm)) |
| December 31, 2024 | [Journey Medical Corp FDA approval](https://sec-api.dev/companies/derm/catalysts) | DERM | dermatological conditions, today | completed, approved | ""we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/tm2510555d1_ex99-1.htm)) |
| December 31, 2024 | [XOLREMDI® (mavorixafor) FDA approval](https://sec-api.dev/pdufa/mavorixafor) | XFOR |  | completed, approved | "For the year ended December 31, 2024, a $7.0 million regulatory milestone payment was incurred and paid after receipt of FDA approval of the Company's NDA on April 26, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1501697/000162828025014805/xfor-20241231.htm)) |
| December 31, 2024 | [Longeveron Inc. earnings report](https://sec-api.dev/companies/lgvn/catalysts) | LGVN |  | completed | "Announces Full-Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1721484/000121390025018776/ea023228401ex99-1_long.htm)) |
| December 31, 2024 | [Radiopharm Theranostics Ltd trial start](https://sec-api.dev/companies/radx/catalysts) | RADX |  | completed | "As at 31 December 2024, milestone 3 for the first patient dosed in the first Phase 1 therapeutic clinical trial have been achieved and paid (30 June 2024: none)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1949257/000121390025018823/ea023256101ex99-1_radiopharm.htm)) |

Other months: https://sec-api.dev/fda-calendar/2024-11 , https://sec-api.dev/fda-calendar/2025-01. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates December 2024: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2024-12

```bibtex
@misc{secapidev_fda_calendar_2024_12_20261116,
  title        = {PDUFA dates December 2024: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2024-12}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2024_12_20261116","title":"PDUFA dates December 2024: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2024-12","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
